519 related articles for article (PubMed ID: 21262992)
21. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
Sarafoff N; Sibbing D; Sonntag U; Ellert J; Schulz S; Byrne RA; Mehilli J; Schömig A; Kastrati A
Thromb Haemost; 2010 Sep; 104(3):626-32. PubMed ID: 20664905
[TBL] [Abstract][Full Text] [Related]
22. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.
Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902
[TBL] [Abstract][Full Text] [Related]
23. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
[TBL] [Abstract][Full Text] [Related]
24. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.
Verschuren JJ; Boden H; Wessels JA; van der Hoeven BL; Trompet S; Heijmans BT; Putter H; Guchelaar HJ; Schalij MJ; Jukema JW
Int J Cardiol; 2013 Sep; 167(6):2882-8. PubMed ID: 22940005
[TBL] [Abstract][Full Text] [Related]
25. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor.
Stockl KM; Le L; Zakharyan A; Harada AS; Solow BK; Addiego JE; Ramsey S
Arch Intern Med; 2010 Apr; 170(8):704-10. PubMed ID: 20421557
[TBL] [Abstract][Full Text] [Related]
26. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction.
Evanchan J; Donnally MR; Binkley P; Mazzaferri E
Clin Cardiol; 2010 Mar; 33(3):168-71. PubMed ID: 20235209
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction.
Depta JP; Lenzini PA; Lanfear DE; Wang TY; Spertus JA; Bach RG; Cresci S
Pharmacogenomics J; 2015 Feb; 15(1):20-5. PubMed ID: 25001880
[TBL] [Abstract][Full Text] [Related]
28. Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.
Puymirat E; Schiele F; Ennezat PV; Coste P; Collet JP; Bonnefoy-Cudraz E; Roul G; Richard P; Simon T; Danchin N
Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):211-9. PubMed ID: 25075006
[TBL] [Abstract][Full Text] [Related]
29. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA
Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970
[TBL] [Abstract][Full Text] [Related]
30. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction.
Fontes-Carvalho R; Albuquerque A; Araújo C; Pimentel-Nunes P; Ribeiro VG
Eur J Gastroenterol Hepatol; 2011 May; 23(5):396-404. PubMed ID: 21464720
[TBL] [Abstract][Full Text] [Related]
31. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A
Thromb Haemost; 2014 Dec; 112(6):1190-7. PubMed ID: 25183544
[TBL] [Abstract][Full Text] [Related]
32. Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry).
Puymirat E; Aïssaoui N; Coste P; Dentan G; Bataille V; Drouet E; Mulak G; Carrié D; Blanchard D; Simon T; Danchin N
Am J Cardiol; 2011 Sep; 108(6):755-9. PubMed ID: 21726837
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
34. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217
[TBL] [Abstract][Full Text] [Related]
35. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
Miao J; Liu R; Li Z
Lancet; 2009 Apr; 373(9670):1171-2; author reply 1172-3. PubMed ID: 19345824
[No Abstract] [Full Text] [Related]
36. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
Bergmeijer TO; Janssen PW; Schipper JC; Qaderdan K; Ishak M; Ruitenbeek RS; Asselbergs FW; van 't Hof AW; Dewilde WJ; Spanó F; Herrman JP; Kelder JC; Postma MJ; de Boer A; Deneer VH; ten Berg JM
Am Heart J; 2014 Jul; 168(1):16-22.e1. PubMed ID: 24952855
[TBL] [Abstract][Full Text] [Related]
37. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Hsiao FY; Mullins CD; Wen YW; Huang WF; Chen PF; Tsai YW
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1043-9. PubMed ID: 21823195
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
Jang JS; Cho KI; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Seol SH; Kim DI; Kim BH; Park YH; Je HG; Jeong YH; Lee SW
Am J Cardiol; 2012 Aug; 110(4):502-8. PubMed ID: 22591668
[TBL] [Abstract][Full Text] [Related]
39. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T
Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030
[TBL] [Abstract][Full Text] [Related]
40. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
